Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC

Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC

Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with specific types of advanced or metastatic cancers. These revelations were spotlighted during the ESMO Congress 2023 and simultaneously found a place in the esteemed New England Journal of Medicine. Key […]

Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS

Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced RET-mutant medullary thyroid cancer (MTC). The Phase 3 clinical trial distinctly highlights Retevmo’s superiority over existing first-line treatments, namely multikinase inhibitors cabozantinib and vandetanib. Retevmo demonstrated a statistically significant and […]

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus pemetrexed in patients diagnosed with RET fusion-positive advanced non-small cell lung cancer (NSCLC). The findings showcased a notable improvement in progression-free survival (PFS), a primary objective of the study. Study […]

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Retevmo (selpercatinib) capsules for the treatment of three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers. The approvals are for the drug to be used in patients whose tumors […]

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Retevmo has also been approved by the FDA for the treatment […]